JG
EWTX icon

Jain Global’s Edgewise Therapeutics EWTX Stock Holding History

Jain Global’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,401
Closed -$1.46M – 1838
2026
Q1 		$1.46M Sell
46,401
-67,455
-59% -$1.95M 0.01% 742
2025
Q4 		$2.83M Buy
+113,856
New +$2.29M 0.01% 529
2025
Q1 		– Sell
-7,850
Closed -$210K – 1156
2024
Q4 		$210K Buy
+7,850
New +$250K 0.01% 634

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jain Global's EWTX Position: Q2 2026 in Review

Jain Global sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 46,401 shares — an estimated $1.46M sold.

Jain Global first reported a position in EWTX in Q4 2024 and held it in 3 quarters. The position peaked at $2.83M in Q4 2025. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Jain Global reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jain Global sold 46,401 Edgewise Therapeutics shares in Q2 2026, an estimated $1.46M.
  • Jain Global first reported a position in Edgewise Therapeutics in Q4 2024 and held it in 3 quarters.
  • Jain Global's Edgewise Therapeutics position peaked at $2.83M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.